Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease

Hayat, Amir

doi:10.3121/cmr.2008.811

Cited by 46 publications

(39 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Железо -питательный компонент для микро организмов, поэтому секвестрация железа в мононуклерной фагоцитарной системе в услови-ях воспаления может рассматриваться в качестве защитного механизма против прогрессирования основного заболевания [84]. Исследования показы-вают, что пациенты с показателем степени насыще-ния трансферрина железа выше 20% и концентраци-ей ферритина > 100 мкг/г, получающие препараты железа парентерально, имеют больший риск бактери-емии, чем пациенты, которые их не получают [85]. 2.…”

Section: вопросы современной педиатрииunclassified

Anemia in Inflammatory Bowel Diseases in Children

Олегович¹,

Потапов²,

Цимбалова³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

Section: вопросы современной педиатрииunclassified

Anemia in Inflammatory Bowel Diseases in Children

Олегович¹,

Потапов²,

Цимбалова³

et al. 2016

Vopr. sovr. pediatr.

View full text Add to dashboard Cite

“…A recent study on the global burden of anemia found that though the prevalence of anemia dropped for both males and females from 1990 to 2010, the global prevalence of anemia was still at a high 32% in 2010, of which the top cause globally was iron-deficiency anemia [8]. There is also a growing recognition that an adequate body supply of iron is important not only to avoid or treat anemia, but also to improve quality of life [9].…”

Section: Introductionmentioning

confidence: 99%

Premedication protocol for iron infusions in patients with anaphylactic reaction to parenteral iron: A case series

Hudon¹,

Sibulo²,

Brady³

2016

IJCRI

View full text Add to dashboard Cite

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations. This report is a case study involving two female patients, 37-year-old and 31-year-old. Both females presented with severe iron-deficiency anemia while intolerant to oral iron and suffered anaphylactic reactions to parenteral iron. The method of intervention involved a premedication protocol, which was initiated immediately prior to iron sucrose infusion. For Case 1, the protocol included 10 mg IV dexamethasone, one duoneb (ipratropium bromide/ albuterol sulfate), normal saline at 60 cc/hour, and 0.1 mg epinephrine given subcutaneously at the start of iron infusion, with 0.3 mg of epinephrine available at the bedside as needed for allergic reaction. For Case 2, the protocol included 50 mg IV diphenhydramine, 10 mg IV dexamethasone, one duoneb, normal saline at 50 cc/hour, 0.3 mg epinephrine at the bedside in case of reaction. Conclusion: Patient iron levels were within normal limits after treatment, and no adverse events, such as anaphylactic reactions, occurred. With a precisely implemented premedication protocol initiated immediately prior to iron infusion, results of this case study indicate that such patients might be successfully and safely treated with parenteral iron. IJCRI publishes

show abstract

“…However, in patients with previous phosphorus-calcium homeostasis disorders, as in the case of the patient reported herein, clinical and laboratory monitoring should be maximised for an early intervention. In addition, comparing the two hypophosphataemia episodes of our patient, it is very likely that the greater delay in the recovery from the first of them was due to the subsequent administration of FeSCS [1,3] Therefore, once hypophosphataemia is detected, it does not appear to be advisable to use any of the two iron molecules until phosphataemia values have returned to normal. …”

Section: Textmentioning

confidence: 99%

“…Hypophosphataemia is a rather common side effect after administration of ferric carboxymaltose (FeCXM); it has been also described, though less frequently and severely, after IV infusion of iron sucrose (FeSCS) [1][2][3]. In these cases, some studies have shown an excessive urinary phosphate loss mediated by the fibroblastic growth factor 23 (FGF23) [4].…”

Section: Textmentioning

confidence: 99%

Iterative and Asymptomatic Hypophosphataemia after Administration of Ferric Carboxymaltose in a Patient Undergoing with Bariatric Surgery

Fernández-Miera¹

2015

EMIJ

View full text Add to dashboard Cite

Context: Hypophosphataemia after administration of ferric carboxymaltose (FeCXM), secondary to excessive urinary phosphate loss mediated by the fibroblastic growth factor 23 (FGF23), is generally asymptomatic, except when the deficiency is very severe.Case Description: A female patient undergoing bariatric surgery experienced, at an early stage vitamin D deficiency with secondary hyperparathyroidism, and, ten and thirteen years after, develop two episodes of severe ferropenia, for which she was administered FeCXM. In both cases develop severe hypophosphatemia coursing in a completely asymptomatic. Conclusion:Unless there is already a previous depletion of phosphorus, hypophosphataemia secondary to FeCXM should not be an obstacle to future administrations. Reusing FeCXM should only be performed when phosphatemia values have recovered.

show abstract

Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease

Cited by 46 publications

References 97 publications

Anemia in Inflammatory Bowel Diseases in Children

Anemia in Inflammatory Bowel Diseases in Children

Premedication protocol for iron infusions in patients with anaphylactic reaction to parenteral iron: A case series

Iterative and Asymptomatic Hypophosphataemia after Administration of Ferric Carboxymaltose in a Patient Undergoing with Bariatric Surgery

Contact Info

Product

Resources

About